All In Biotech

Drug Trial Radar · NCT03395392

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

A Randomized, Double-Blind Controlled Comparison of NRX-101 to Lurasidone for Adults With Bipolar Depression and Subacute Suicidal Ideation or Behavior

Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

74

Actual

Start

May 12, 2022

Primary completion

Feb 28, 2024

Study completion Mar 30, 2024

Sponsor

Lead sponsor
NeuroRx, Inc.Industry
Sponsor type
Industry
Collaborators
Prevail Infoworks
First posted
Jan 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression with suicidal ideation. This study will test the hypothesis that NRX-101 is superior to lurasidone alone (standard of care) in maintaining remission from symptoms of depression (primary endpoint) and suicidal ideation or behavior (declared secondary endpoint) over a six week period of twice-daily oral dosing.

Conditions

  • Bipolar Depression
  • Suicidal Ideation and Behavior

Interventions

  • NRX-101Drug

    NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

  • Lurasidone HClDrug

    Lurasidone HCl will be given twice a day by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in MADRS-10 over 42 DaysTime frame: Six weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Science 37

    Culver City, California

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida

  • ACMR

    Atlanta, Georgia

  • iResearch Atlanta, LLC

    Decatur, Georgia

  • iResearch Savannah

    Savannah, Georgia

  • CBH Health

    Gaithersburg, Maryland

  • Omaha Insomnia and Psychiatric Services

    Omaha, Nebraska

  • Dent Neurologic Institute

    Amherst, New York

  • Peace Health Medical Group

    Eugene, Oregon

  • University of Texas Health Austin

    Austin, Texas

  • Roots Behavioral Health

    Austin, Texas

  • JPS Health

    Fort Worth, Texas

  • Houston Mind and Brain

    Houston, Texas

  • Health Texas

    Richmond, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.